SRR934869
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 88.30486202365309
- age_years
- 38
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.552
- MYC_TARGETS_V2+0.535
- UNFOLDED_PROTEIN_RESPONSE+0.518
- INTERFERON_GAMMA_RESPONSE+0.470
- TNFA_SIGNALING_VIA_NFKB+0.465
- ALLOGRAFT_REJECTION+0.459
- E2F_TARGETS+0.458
- IL6_JAK_STAT3_SIGNALING+0.454
- MTORC1_SIGNALING+0.433
- PROTEIN_SECRETION+0.433
Top 10 suppressed
- KRAS_SIGNALING_DN-0.397
- ESTROGEN_RESPONSE_LATE-0.301
- BILE_ACID_METABOLISM-0.285
- MYOGENESIS-0.258
- SPERMATOGENESIS-0.185
- APICAL_SURFACE-0.160
- ESTROGEN_RESPONSE_EARLY-0.144
- PANCREAS_BETA_CELLS-0.118
- PEROXISOME-0.098
- FATTY_ACID_METABOLISM-0.045
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | B27956E8-3374-4720-9F80-7CE6FE7C7690 | — | — | 0.938 |
| 2 | 8B0BED75-8B6D-4838-9CE0-425EBFE33A44 | — | — | 0.937 |
| 3 | 1B940F72-3C90-43C4-9267-185F21D10AC9 | — | — | 0.935 |
| 4 | SRR934835 | — | — | 0.935 |
| 5 | D5191F3D-028E-401C-927E-483F6884BE39 | — | — | 0.933 |
| 6 | SRR934936 | — | — | 0.932 |
| 7 | SRR934881 | — | — | 0.932 |
| 8 | TCGA-XF-A9SY-01A-21R-A42T-07 | — | — | 0.930 |
| 9 | D494D692-9EC2-429A-A0FE-696D2A152D4A | — | — | 0.928 |
| 10 | 7AA08B08-B1DD-47AB-A0F2-850F6DE95093 | — | — | 0.926 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.552 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.535 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.518 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.465 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.459 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.458 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.454 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.433 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.433 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.414 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.411 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.372 | Inavolisib | — uncovered |
| HYPOXIA | 0.346 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.339 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.335 | Inavolisib | — uncovered |
| APOPTOSIS | 0.319 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.314 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.307 | Inavolisib | — uncovered |